Key facts
- It has raised $23.6M; the latest was Later Stage VC ($2.6M) in Mar 2025.
- Notable investors include National Institutes of Health, Coalition for Epidemic Preparedness Innovations.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Uvax Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Uvax Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Uvax Bio
Operator of a biotechnology company intended to create nanoparticle vaccine through antigen design. The company's platform develops and commercializes B-cell-focused, rapid antibody-eliciting vaccines for challenging diseases and solving infectious disease threats by combining rational antigen design and protein engineering to create virus-like particle vaccines, enabling patients to fight against various types of viruses and tuberculosis.
- Sector
- Healthcare
- HQ
- Newark, DE, United States
- Founded
- 2018
- Employees
- 14
- Website
- uvaxbio.com/
- Ownership
- Privately Held (backing)
Uvax Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Uvax Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Uvax Bio in its N-PORT filings yet. We sweep new filings monthly.